Environmental Health and Preventive Medicine

, Volume 14, Issue 2, pp 71–87

Molecular epidemiology of major depressive disorder

Review

Abstract

Major depressive disorder causes significant morbidity, affecting people’s ability to work, function in relationships, and engage in social activities. Moreover, major depressive disorder increases the risk of suicidal ideation, attempted suicide and death by completed suicide. There is evidence that chronic stress can cause major depressive disorder. As for genetic factors, only minor susceptibility genes have been reliably identified. The serotonin system provides a logical source of susceptibility genes for depression, because this system is the target of selective serotonin reuptake-inhibitor drugs that are effective in treating depression. The 5-hydroxytryptamine (serotonin) transporter (5-HTT) has received particular attention because it is involved in the reuptake of serotonin at brain synapses. One common polymorphic variant of the 5-HTT-linked polymorphic region (5-HTTLPR), which affects the promoter of the 5-HTT gene, causes reduced uptake of the neurotransmitter serotonin into the presynaptic cells in the brain. The authors discussed the relationship between genetic polymorphisms and major depressive disorder, with special emphasis on the 5-HTTTLPR polymorphism. As the 5-HTTLPR polymorphism was significantly associated with an increased risk of major depressive disorder, the 5-HTT gene may be a candidate for a major depressive disorder susceptibility gene. As major depressive disorder is a multifactorial disease, an improved understanding of the interplay of environmental and genetic polymorphisms at multiple loci may help identify individuals who are at increased risk for major depressive disorder. Hopefully, in the future we will be able to screen for major depressive disorder susceptibility by using specific biomarkers.

Keywords

5-Hydroxytryptamine (serotonin) transporter gene (5-HTTMajor depressive disorder Epidemiology Genetic polymorphism Meta-analysis 

References

  1. 1.
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association; 1994.Google Scholar
  3. 3.
    Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry. 1970;117:437–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992;268:3441–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry. 2001;62(Suppl 25):27–30.PubMedGoogle Scholar
  6. 6.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th ed. Washington: American Psychiatric Publishing Inc; 2000.Google Scholar
  7. 7.
    Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329–35.PubMedCrossRefGoogle Scholar
  8. 8.
    Institute of Medicine. Unequal treatment: confronting racial and ethnic disparities in health care (March 2002). http://www.iom.edu/report.asp?id=4475. Accessed 20 March 2002.
  9. 9.
    US Public Health Service. Substance abuse and mental health administration. Mental health: culture, race, and ethnicity; a supplement to mental health: a report of the surgeon general. http://www.surgeongeneral.gov/library/mentalhealth/cre/.
  10. 10.
    Japanese Ministry of Health, Labor and Welfare. Vital statistics of Japan 2005. Tokyo: Health and Welfare Statistics Association; 2006.Google Scholar
  11. 11.
    Kendler KS. Overview: a current perspective on twin studies of schizophrenia. Am J Psychiatry. 1983;140:1413–25.PubMedGoogle Scholar
  12. 12.
    Kessler RC. The effects of stressful life events on depression. Annu Rev Psychol. 1997;48:191–214.PubMedCrossRefGoogle Scholar
  13. 13.
    Mazure CM. Life stressors as risk factors in depression. Clin Psychol Sci Pract. 1998;5:291–313.CrossRefGoogle Scholar
  14. 14.
    Monroe SM, Hadjiyannakis K. The social environment and depression: focusing on severe life stress. In: Gotlib IH, Hammen CL, editors. Handbook of Depression. New York: Guilford Press; 2002. p. 314–40.Google Scholar
  15. 15.
    Tennant C. Life events, stress and depression: a review of the findings. Aust NZ J Psychiatry. 2002;36:173–82.CrossRefGoogle Scholar
  16. 16.
    Paykel ES. Life events and affective disorders. Acta Psychiatr Scand. 2003;108:61–6.CrossRefGoogle Scholar
  17. 17.
    Hammen C. Stress and depression. Annu Rev Clin Psychol. 2005;1:293–319.PubMedCrossRefGoogle Scholar
  18. 18.
    Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55–68.PubMedCrossRefGoogle Scholar
  19. 19.
    Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001;2:343–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Edgerton JE, Campbell RE, editors. American psychiatric glossary. 7th ed. Washington: American Psychiatric Press Inc; 1994.Google Scholar
  22. 22.
    Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Goetzel RZ, Hawkins K, Ozminski RJ. The health and productivity cost burden of the “top 10” physical and mental conditions affecting six large US employers in 1999. J Occup Environ Med. 2003;45:5–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.Google Scholar
  25. 25.
    Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–92.PubMedCrossRefGoogle Scholar
  26. 26.
    WHO International Consortium in Psychiatric Epidemiology. Cross-national comparisons of the prevalences and correlates of mental disorders Bulletin of the World Health Organization v.78 n.4. 2000.Google Scholar
  27. 27.
  28. 28.
  29. 29.
    Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. Br J Psychiatry. 2001;178:145–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 1998;33:587–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.PubMedGoogle Scholar
  32. 32.
    Offord DR, Boyle MH, Campbell D, Goering P, Lin E, Wong M, et al. One-year prevalence of psychiatric disorder in Ontarians 15–64 years of age. Can J Psychiatry. 1996;41:559–63.PubMedGoogle Scholar
  33. 33.
    Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry. 1988;45:977–86.PubMedGoogle Scholar
  34. 34.
    Evans K, McGrath J, Milns R. Searching for schizophrenia in ancient Greek and Roman literature: a systematic review. Acta Psychiatr Scand. 2003;107:323–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen H-U. Sex differences in rates of depression: cross-national perspectives. J Affect Disord. 1993;29:77–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Gater R, Tansella M, Korten A, Tiemens BG, Mavreas VG, Olatawura MO. Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings. Arch Gen Psychiatry. 1998;55:405–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Bennett DS, Ambrosini PJ, Kudes D, Metz C, Rabinovich H. Gender differences in adolescent depression: do symptoms differ for boys and girls? J Affect Disord. 2005;89:35–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. 2007;101:27–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Hawton K. Sex and suicide. Gender differences in suicidal behaviour. Br J Psychiatry. 2000;177:484–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Biddle L, Gunnell D, Sharp D, Donovan JL. Factors influencing help seeking in mentally distressed young adults: a cross-sectional survey. Br J Gen Pract. 2004;54:248–53.PubMedGoogle Scholar
  42. 42.
    Bogner HR, Gallo JJ. Are higher rates of depression in women accounted for by differential symptom reporting? Soc Psychiatry Psychiatr Epidemiol. 2004;39:126–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Gunnell D, Rasul F, Stansfeld SA, Hart CL, Davey SG. Gender differences in self-reported minor mental disorder and its association with suicide. A 20-year follow-up of the Renfrew and Paisley cohort. Soc Psychiatry Psychiatr Epidemiol. 2002;37:457–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Haynie DA, Berg S, Johansson B, Gatz M, Zarit SH. Symptoms of depression in the oldest old: a longitudinal study. J Gerontol B Psychol Sci Soc Sci. 2001;56:P111–8.PubMedGoogle Scholar
  45. 45.
    Kasen S, Cohen P, Chen H, Castille D. Depression in adult women: age changes and cohort effects. Am J Public Health. 2003;93:2061–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276:293–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151:979–86.PubMedGoogle Scholar
  48. 48.
    Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder. JAMA. 2003;289:3095–105.PubMedCrossRefGoogle Scholar
  49. 49.
    US Department of Health and Human Services. Mental health: culture, race, and ethnicity: a supplement to mental health: a report of the surgeon general—executive summary. Rockville: US Dept of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001.Google Scholar
  50. 50.
    Breslau J, Kendler KS, Su M, Gaxiola-Aguilar S, Kessler RC. Lifetime risk and persistence of psychiatric disorders across ethnic groups in the United States. Psychol Med. 2005;35:317–27.PubMedCrossRefGoogle Scholar
  51. 51.
    Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry. 2004;49:124–38.PubMedGoogle Scholar
  52. 52.
    Dunlop DD, Song J, Lyons JS, Manheim LM, Chang RW. Racial/ethnic differences in rates of depression among preretirement adults. Am J Public Health. 2003;93:1945–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Kawakami N, Takeshima T, Ono Y, Uda H, Hata Y, Nakane Y, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002–2003. Psychiatry Clin Neurosci 2005; 59:441–52.Google Scholar
  54. 54.
  55. 55.
    Riolo SA, Nguyen TA, Greden JF, King CA. Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health. 2005;95:998–1000.PubMedCrossRefGoogle Scholar
  56. 56.
    Straub RH, Dhabhar FS, Bijlsma JW, Cutolo M. How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. Arthr Rheum. 2005;52:16–26.CrossRefGoogle Scholar
  57. 57.
    Dhabhar FS, McEwen BS. Acute stress enhances while chronic stress suppresses immune function in vivo: a potential role for leukocyte trafficking. Brain Behav Immun. 1997;11:286–306.PubMedCrossRefGoogle Scholar
  58. 58.
    Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA. 1999;96:1059–64.PubMedCrossRefGoogle Scholar
  59. 59.
    Dhabhar FS, McEwen BS. Stress-induced enhancement of antigen-specific cell-mediated immunity. J. Immunol. 1996;156:2608–15.PubMedGoogle Scholar
  60. 60.
    McEwen BS. Protective and damaging effects of stress mediators: allostasis and allostatic load. N Engl J Med. 1998;338:171–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000.PubMedCrossRefGoogle Scholar
  62. 62.
    Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev. 1984;5:25–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Schleimer RP, Claman HN, Oronsky A, editors. Anti-inflammatory steroid action: basic and clinical aspect. San Diego: Academic Press, Inc.; 1989.Google Scholar
  64. 64.
    Dohrenwend BP, Levav I, Shrout PE, Schwartz S, Naveh G, Link BG, et al. Socioeconomic status and psychiatric disorders: the causation-selection issue. Science. 1992;255:946–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Bruce ML, Hoff RA. Social and physical health risk factors for first-onset major depressive disorder in a community sample. Soc Psychiatry Psychiatr Epidemiol. 1994;29:165–71.PubMedGoogle Scholar
  66. 66.
    Swindle RW, Cronkite RC, Moos RH. Life stressors, social resources, coping, and the 4-year course of unipolar depression. J Abnorm Psychol. 1989;98:468–77.PubMedCrossRefGoogle Scholar
  67. 67.
    Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54:208–15.PubMedCrossRefGoogle Scholar
  68. 68.
    Breslau N, Davis GC. Chronic stress and major depression. Arch Gen Psychiatry. 1986;43:309–14.PubMedGoogle Scholar
  69. 69.
    Paykel ES, Cooper Z. Life events and social stress. In: Paykel ES, editor. Handbook of affective disorder. New York: Guilford Press; 1992. p. 149–70.Google Scholar
  70. 70.
    Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review and meta-analysis. Am J Psychiatry. 2000;157:1552–62.PubMedCrossRefGoogle Scholar
  71. 71.
    Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ, et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry. 1999;56:557–63.PubMedCrossRefGoogle Scholar
  72. 72.
    Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch Gen Psychiatry. 1993;50:863–70.PubMedGoogle Scholar
  73. 73.
    Kendler KS, Gardner CO, Neale MC, Prescott CA. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes? Psychol Med. 2001;31:605–16.PubMedGoogle Scholar
  74. 74.
    McGuffin P, Katz R, Rutherford J. Nature, nurture and depression: a twin study. Psychol Med. 1991;21:329–55.PubMedCrossRefGoogle Scholar
  75. 75.
    McGuffin P, Katz R, Watkins S, Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry. 1996;53:129–36.PubMedGoogle Scholar
  76. 76.
    Torgersen S. Genetic factors in moderately severe and mild affective disorders. Arch Gen Psychiatry. 1986;43:222–6.PubMedGoogle Scholar
  77. 77.
    Mendlewicz J, Rainer JD. Adoption study supporting genetic transmission in manic-depressive illness. Nature. 1977;268:326–9.CrossRefGoogle Scholar
  78. 78.
    Cadoret R. Evidence for genetic inheritance of primary affective disorder in adoptees. Am J Psychiatry. 1978;133:463–6.Google Scholar
  79. 79.
    Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry. 1986;43:923–9.PubMedGoogle Scholar
  80. 80.
    Gershon ES, Weissman MM, Guroff JJ, Prusoff BA, Leckman JF. Validation of criteria for major depression through controlled family study. J Affect Disord. 1986;11:125–31.PubMedCrossRefGoogle Scholar
  81. 81.
    Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, et al. Psychiatric disorders in the relatives of probands with affective disorders The Yale University, National Institute of Mental Health Collaborative Study. Arch Gen Psychiatry. 1984;41:13–21.PubMedGoogle Scholar
  82. 82.
    Maier W, Lichtermann D, Minges J, Heun R, Hallmayer J, Benkert O. Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? Evidence from a family study. Am J Psychiatry. 1992;149:1666–73.PubMedGoogle Scholar
  83. 83.
    Bunney WE, Davis JM. Noradrenaline in depressive reactions. A review. Arch Gen Psychiatry. 1965;13:483–94.PubMedGoogle Scholar
  84. 84.
    Schildkraut JJ, Gordon EK, Durell J. Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J Psychiatr Res. 1965;3:213–28.PubMedCrossRefGoogle Scholar
  85. 85.
    Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113:1237–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47:411–8.PubMedGoogle Scholar
  87. 87.
    Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry. 1996;53:117–28.PubMedGoogle Scholar
  88. 88.
    Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621–4.PubMedGoogle Scholar
  89. 89.
    Heils A, Mößner R, Lesch KP. The human serotonin transporter gene polymorphism-basic research and clinical implications. J Neural Transm. 1997;104:1005–14.PubMedCrossRefGoogle Scholar
  90. 90.
    Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996;1:453–60.PubMedGoogle Scholar
  91. 91.
    McKenzie A, Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA. 1999;96:15251–5.CrossRefGoogle Scholar
  92. 92.
    Abbar M, Courtet P, Amadéo S, Caer Y, Mallet J, Baldy-Moulinier MC, et al. Suicidal behaviors and the tryptophan hydroxylase gene. Arch Gen Psychiatry. 1995;52:846–9.PubMedGoogle Scholar
  93. 93.
    Peroutka SJ. 5-Hydroxytryptamine receptor subtypes. Ann Rev Neurosci. 1988;11:45–60.PubMedCrossRefGoogle Scholar
  94. 94.
    Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry. 1994;51:34–8.PubMedGoogle Scholar
  95. 95.
    Du L, Bakish D, Hrdina PD. Tryptophan hydroxylase gene 218A/C polymorphism is associated with somatic anxiety in major depressive disorder. J Affect Disord. 2001;65:37–44.PubMedCrossRefGoogle Scholar
  96. 96.
    Gizatullin R, Zaboli G, Jönsson EG, Asberg M, Leopardi R. The tryptophan hydroxylase (TPH) 2 gene unlike TPH-1 exhibits no association with stress-induced depression. J Affect Disord. 2008;107:175–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Jokela M, Räikkönen K, Lehtimäki T, Rontu R, Keltikangas-Järvinen L. Tryptophan hydroxylase 1 gene (TPH1) moderates the influence of social support on depressive symptoms in adults. J Affect Disord. 2007;100:191–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Christenson JG, Dairman W, Udenfriend S. On the identity of DOPA decarboxylase and 5-hydroxytryptophan decarboxylase (immunological titration-aromatic l-amino acid decarboxylase–serotonin– dopamine–norepinephrine). Proc Natl Acad Sci USA. 1972;69:343–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202–10.PubMedCrossRefGoogle Scholar
  100. 100.
    Massat I, Souery D, Del-Favero J, Nothen M, Blackwood D, Muir W, et al. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry. 2005;10:598–605.PubMedCrossRefGoogle Scholar
  101. 101.
    Ohara K, Nagai M, Suzuki Y, Ohara K. Low activity allele of the catechol-O-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9:1305–8.PubMedGoogle Scholar
  102. 102.
    Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533–54.PubMedCrossRefGoogle Scholar
  103. 103.
    Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296–320.PubMedCrossRefGoogle Scholar
  104. 104.
    Pucadyil TJ, Chattopadhyay A. Cholesterol modulates the antagonist-binding function of hippocampal serotonin1A receptors. Biochim Biophys Acta. 2005;1714:35–42.PubMedCrossRefGoogle Scholar
  105. 105.
    Dubovsky SL, Thomas M. Serotonergic mechanisms and current and future psychiatric practice. J Clin Psychiatry. 1995;56(Suppl 2):38–48.PubMedGoogle Scholar
  106. 106.
    Kapur S, Remigton G. Serotonin–Dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466–76.PubMedGoogle Scholar
  107. 107.
    Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11] WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106–13.PubMedCrossRefGoogle Scholar
  108. 108.
    Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23:8788–99.PubMedGoogle Scholar
  109. 109.
    Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23:563–7.PubMedCrossRefGoogle Scholar
  110. 110.
    Duman RS, Charney DS. Cell atrophy and loss in major depression. Biol Psychiatry. 1999;45:1083–4.PubMedCrossRefGoogle Scholar
  111. 111.
    Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25.PubMedCrossRefGoogle Scholar
  112. 112.
    Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF, et al. BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacol. 2005;30:1353–61.Google Scholar
  113. 113.
    Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 2005;58:307–14.PubMedCrossRefGoogle Scholar
  114. 114.
    Strauss J, Barr CL, George CJ, King N, Shaikh S, Devlin B, et al. Association study of brain-derived neurotrophic factor in adults with a history of childhood onset mood disorder. Am J Med Genet B Neuropsychiatr Genet. 2004;131B:6–9.CrossRefGoogle Scholar
  115. 115.
    Surtees PG, Wainwright NW, Willis-Owen SA, Sandhu MS, Luben R, Day NE, et al. No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J Psychiatr Res. 2007;41:404–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Cohen S, Rosa A, Corsico A, Sterne A, Owen M, Korzsun A, et al. The brain derived neurotrophic factor (BDNF) Val66Met polymorphism and recurrent unipolar depression. Am J Med Genet B Neuropsychiatr Genet. 2004;130B:37–8.Google Scholar
  117. 117.
    Kim CH, Kim HS, Cubells JF, Kim KS. A previously undescribed intron and extensive 5′ upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem. 1999;274:6507–18.PubMedCrossRefGoogle Scholar
  118. 118.
    Meyer J, Wiedemann P, Okladnova O, Brüss M, Staab T, Stöber G, et al. Cloning and functional characterization of the human norepinephrine transporter gene promoter. J Neural Transm. 1998;105:1341–50.PubMedCrossRefGoogle Scholar
  119. 119.
    Chang CC, Lu RB, Chen CL, Chu CM, Chang HA, Huang CC, et al. Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population. J Psychiatry Neurosci. 2007;32:121–8.PubMedGoogle Scholar
  120. 120.
    Inoue K, Itoh K, Yoshida K, Higuchi H, Kamata M, Takahashi H, et al. No association of the G1287A polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Biol Pharm Bull. 2007;30:1996–8.PubMedCrossRefGoogle Scholar
  121. 121.
    Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59:11–4.PubMedGoogle Scholar
  122. 122.
    Kahn RS, Davis KL. New developments in dopamine and schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the Fourth Generation of Progress. New York: Raven Press; 1995.Google Scholar
  123. 123.
    Souery D, Lipp O, Mahieu B, Mendelbaum K, De Bruyn A, De Maertelaer V, et al. Excess of tyrosine hydroxylase restriction fragment length polymorphism homozygosity in unipolar but not bipolar patients: a preliminary report. Biol Psychiatry. 1996;40:305–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Lim LC, Gurling H, Curtis D, Brynjolfsson J, Petursson H, Gill M. Linkage between tyrosine hydroxylase gene and affective disorder cannot be excluded in two of six pedigrees. Am J Med Genet. 1993;48:223–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Serretti A, Macciardi F, Verga M, Cusin C, Pedrini S, Smeraldi E. Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder. Am J Med Genet. 1998;81:127–30.PubMedCrossRefGoogle Scholar
  126. 126.
    Furlong RA, Rubinsztein JS, Ho L, Walsh C, Coleman TA, Muir WJ, et al. Analysis and metaanalysis of two polymorphisms within the tyrosine hydroxylase gene in bipolar and unipolar affective disorders. Am J Med Genet. 1999;88:88–94.PubMedCrossRefGoogle Scholar
  127. 127.
    Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347:146–51.PubMedCrossRefGoogle Scholar
  128. 128.
    Willner P, Muscat R, Phillips G. The role of dopamine in rewarded behavior: ability, insight, drive or incentive? Pol J Pharmacol Pharm. 1991;43:291–300.PubMedGoogle Scholar
  129. 129.
    Willner P, Muscat R, Papp M. An animal model of anhedonia. Clin Neuropharmacol. 1992;15:550–1.Google Scholar
  130. 130.
    Civelli O, Bunzow JR, Grandy DK. Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol. 1993;33:281–307.PubMedCrossRefGoogle Scholar
  131. 131.
    Ross EM, Gilman AG. Biochemical properties of hormone-sensitive adenylate cyclase. Annu Rev Biochem. 1980;49:533–64.PubMedCrossRefGoogle Scholar
  132. 132.
    Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997;6:577–82.PubMedCrossRefGoogle Scholar
  133. 133.
    Jönsson EG, Nöthen MM, Grünhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4:290–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem. 1996;271:26013–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti EK, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998;3:256–60.PubMedCrossRefGoogle Scholar
  136. 136.
    Jönsson EG, Flyckt L, Burgert E, Crocq MA, Forslund K, Mattila-Evenden M, et al. Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet. 2003;13:1–12.PubMedCrossRefGoogle Scholar
  137. 137.
    Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, et al. Multiple dopamine D4 receptor variants in the human population. Nature. 1992;358:149–52.PubMedCrossRefGoogle Scholar
  138. 138.
    Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. 1995;65:1157–65.PubMedGoogle Scholar
  139. 139.
    Manki H, Kanba S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, et al. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord. 1996;40:7–13.PubMedCrossRefGoogle Scholar
  140. 140.
    Rees M, Norton N, Jones I, McCandless F, Scourfield J, Holmans P, et al. Association studies of bipolar disorder at the human serotonin transporter gene (hSERT; 5HTT). Mol Psychiatry. 1997;2:398–402.PubMedCrossRefGoogle Scholar
  141. 141.
    Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry. 2004;61:177–83.PubMedCrossRefGoogle Scholar
  142. 142.
    Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C, Kugel H, et al. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacol. 2008;33:418–24.CrossRefGoogle Scholar
  143. 143.
    Hoehe MR, Wendel B, Grunewald I, Chiaroni P, Levy N, Morris-Rosendahl D, et al. Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. Am J Med Genet. 1998;81:1–3.PubMedCrossRefGoogle Scholar
  144. 144.
    Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, et al. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry. 1999;4:389–92.PubMedCrossRefGoogle Scholar
  145. 145.
    Geijer T, Frisch A, Persson ML, Wasserman D, Rockah R, Michaelovsky E, et al. Search for association between suicide attempt and serotonergic polymorphisms. Psychiatr Genet. 2000;10:19–26.PubMedCrossRefGoogle Scholar
  146. 146.
    Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry. 2005;62:537–44.PubMedCrossRefGoogle Scholar
  147. 147.
    Grünblatt E, Löffler C, Zehetmayer S, Jungwirth S, Tragl KH, Riederer P, et al. Association study of the 5-HTTLPR polymorphism and depression in 75-year-old non-demented subjects from the Vienna Transdanube Aging (VITA) study. J Clin Psychiatry. 2006;67:1373–8.PubMedCrossRefGoogle Scholar
  148. 148.
    Bellivier F, Henry C, Szöke A, Schürhoff F, Nosten-Bertrand M, Feingold J, et al. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci Lett. 1998;255:143–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, et al. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet. 1998;81:58–63.PubMedCrossRefGoogle Scholar
  150. 150.
    Minov C, Baghai TC, Schüle C, Zwanzger P, Schwarz MJ, Zill P, et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett. 2001;303:119–22.PubMedCrossRefGoogle Scholar
  151. 151.
    Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E. Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry. 2002;7:95–9.PubMedCrossRefGoogle Scholar
  152. 152.
    Cervilla JA, Rivera M, Molina E, Torres-González F, Bellón JA, Moreno B, et al. The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:912–7.PubMedCrossRefGoogle Scholar
  153. 153.
    Dorado P, Peñas-Lledó EM, González AP, Cáceres MC, Cobaleda J, Llerena A. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundam Clin Pharmacol. 2007;21:451–3.PubMedCrossRefGoogle Scholar
  154. 154.
    Hickie IB, Naismith SL, Ward PB, Scott EM, Mitchell PB, Schofield PR, et al. Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. J Affect Disord. 2007;98:137–42.PubMedCrossRefGoogle Scholar
  155. 155.
    Hauser J, Leszczyńska A, Samochowiec J, Czerski PM, Ostapowicz A, Chlopocka M, et al. Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. Eur Psychiatry. 2003;18:129–32.PubMedCrossRefGoogle Scholar
  156. 156.
    Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry. 2005;57:247–51.PubMedCrossRefGoogle Scholar
  157. 157.
    Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2:457–62.PubMedCrossRefGoogle Scholar
  158. 158.
    Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K. Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res. 1998;81:117–23.PubMedCrossRefGoogle Scholar
  159. 159.
    Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 2000;11:215–9.PubMedGoogle Scholar
  160. 160.
    Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet. 2004;14:121–9.PubMedCrossRefGoogle Scholar
  161. 161.
    Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet Part B. 2005;133B:110–5.CrossRefPubMedGoogle Scholar
  162. 162.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  163. 163.
    Mendlewicz J, Massat I, Souery D, Del-Favero J, Oruc L, Nöthen MM, et al. Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur J Hum Genet. 2004;12:377–82.PubMedCrossRefGoogle Scholar
  164. 164.
    Matullo G, Peluso M, Polidoro S, Guarrera S, Munnia A, Krogh V, et al. Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol Biomarkers Prev. 2003;12:674–7.PubMedGoogle Scholar
  165. 165.
    Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMedGoogle Scholar
  166. 166.
    Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev. 2002;11:1544–9.PubMedGoogle Scholar
  167. 167.
    Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis. 2002;23:381–7.PubMedCrossRefGoogle Scholar
  168. 168.
    Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depressive disorder. Lancet. 1996;347:731–3.PubMedCrossRefGoogle Scholar
  169. 169.
    Stöber G, Heils A, Lesch KP. Serotonin transporter gene polymorphism and affective disorder. Lancet. 1996;347:1340–1.PubMedCrossRefGoogle Scholar
  170. 170.
    Gutiérrez B, Pintor L, Gastó C, Rosa A, Bertranpetit J, Vieta E, et al. Variability in the serotonin transporter gene and increased risk for major depressive disorder with melancholia. Hum Genet. 1998;103:319–22.PubMedCrossRefGoogle Scholar
  171. 171.
    Mellerup E, Bennike B, Bolwig T, Dam H, Hasholt L, Jørgensen MB, et al. Platelet serotonin transporters and the transporter gene in control subjects, unipolar patients and bipolar patients. Acta Psychiatr Scand. 2001;103:229–33.PubMedCrossRefGoogle Scholar
  172. 172.
    Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, et al. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport. 1996;7:1675–9.PubMedCrossRefGoogle Scholar
  173. 173.
    Liu W, Gu N, Feng G, Li S, Bai S, Zhang J, et al. Tentative association of the serotonin transporter with schizophrenia and unipolar depression but not with bipolar disorder in Han Chinese. Pharmacogenetics. 1999;9:491–5.PubMedGoogle Scholar
  174. 174.
    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.PubMedCrossRefGoogle Scholar
  175. 175.
    Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362–4.PubMedCrossRefGoogle Scholar
  176. 176.
    Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413–6.PubMedGoogle Scholar
  177. 177.
    d’Errico A, Taioli E, Chen X, Vineis P. Genetic metabolic polymorphisms and risk of cancer: a review of the literature. Biomerkers. 1996;1:149–73.CrossRefGoogle Scholar
  178. 178.
    Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239–48.PubMedGoogle Scholar
  179. 179.
    Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. Role of genotype in the cycle of violence in maltreated children. Science. 2002;297:851–4.PubMedCrossRefGoogle Scholar
  180. 180.
    Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P, et al. Gene–environment interaction analysis or serotonin system markers with adolescent depression. Mol Psychiatry. 2004;9:908–15.PubMedCrossRefGoogle Scholar
  181. 181.
    Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA. 2004;101:17316–21.PubMedCrossRefGoogle Scholar
  182. 182.
    Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry. 2005;62:529–35.PubMedCrossRefGoogle Scholar
  183. 183.
    Grabe HJ, Lange M, Wolff B, Volzke H, Lucht M, Freyberger HJ, et al. Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry. 2005;10:220–4.PubMedCrossRefGoogle Scholar
  184. 184.
    Zalsman G, Huang YY, Oquendo MA, Burke AK, Hu XZ, Brent DA, et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry. 2006;163:1588–93.PubMedCrossRefGoogle Scholar
  185. 185.
    Sjöberg RL, Nilsson KW, Nordquist N, Ohrvik J, Leppert J, Lindström L, et al. Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene. Int J Neuropsychopharmacol. 2006;9:443–9.PubMedCrossRefGoogle Scholar
  186. 186.
    Wilhelm K, Mitchell PB, Niven H, Finch A, Wedgwood L, Scimone A, et al. Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry. 2006;188:210–5.PubMedCrossRefGoogle Scholar
  187. 187.
    Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG. The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med. 2005;35:101–11.PubMedCrossRefGoogle Scholar
  188. 188.
    Surtees PG, Wainwright NW, Willis-Owen SA, Luben R, Day NE, Flint J. Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder. Biol Psychiatry. 2006;59:224–9.PubMedCrossRefGoogle Scholar
  189. 189.
    Brown GW, Harris TO. Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene–environment interaction. J Affect Disord. 2008;111:1–12.PubMedCrossRefGoogle Scholar
  190. 190.
    Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science. 2001;293:489–93.PubMedCrossRefGoogle Scholar
  191. 191.
    Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics. 2000;1:15–26.PubMedCrossRefGoogle Scholar
  192. 192.
    Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer’s disease. Genome Res. 2001;11:143–51.PubMedCrossRefGoogle Scholar
  193. 193.
    Khoury M, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. Monographs in epidemiology and biostatistics. New York: NY Oxford University Press; 1993. p. 144–5.Google Scholar
  194. 194.
    Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res. 2001;11:2115–9.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Hygiene 2009

Authors and Affiliations

  1. 1.Department of Preventive Medicine, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of Hygiene, School of MedicineWakayama Medical UniversityWakayamaJapan

Personalised recommendations